Everyone knows how important it is to catch breast cancer in its early stages. What is often guessed at is the level of treatment needed to prevent additional recurrences. Now based on a new study, there may be a new protocol available to evaluate the tumor and to establish the level of treatment a patient should receive.
According to NPR,
Researchers in the U.S. and Sweden used a diagnostic test called MammaPrint to measure a tumor’s genomic “fingerprint” and compared it with survival time after a tumor was removed. They say they were able to pinpoint patients who had a very low risk of death from breast cancer — even up to 20 years after the first diagnosis.
Oncologists are excited about the possibilities of the MammaPrint but are calling for more research to be done before it becomes a standard protocol.